| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
Sermorelin acetate [GRF (1-29) amide (human)] is a peptide compound composed of 29-amino acids, and is a growth hormone-releasing hormone (GHRH) analogue used as a diagnostic agent. It is the shortest fully functional fragment of GHRH and is used as a diagnostic agent to assess growth hormone (GH) secretion. It is also used as doping agent in sports due to its correlation with increased growth of muscular and skeletal tissue.[citation needed] Sermorelin use is also hypothesized to improve deep rapid eye movement sleep.
| Targets |
GHRH analog
|
|---|---|
| ln Vitro |
Sermorelin binds to the growth hormone releasing hormone receptor and mimics native GRF in its ability to stimulate growth hormone secretion.
|
| ln Vivo |
Sermorelin is used in the treatment of children with growth hormone deficiency or growth failure. Geref increases plasma growth hormone (GH) concentration by stimulating the pituitary gland to release GH. Geref is similar to the full-length native hormone (44 residues) in its ability to stimulate GH secretion in humans.
|
| ADME/Pharmacokinetics |
Biological half-life: 11-12 minutes
|
| Toxicity/Toxicokinetics |
Depending on state or federal labeling requirements, termorelin acetate may cause developmental toxicity.
|
| References |
[1]. Drug Test Anal. 2016 Mar;8(3-4):398-401.
|
| Additional Infomation |
Sermorelin acetate may cause developmental toxicity depending on state or federal labeling requirements. Sermorelin is the bioactive fragment of human growth hormone releasing factor, consisting of a GHRH(1-29)-amide. This N-terminal sequence is identical in many mammals, such as humans, pigs, and cattle. It is used to diagnose or treat patients with growth hormone deficiency. See also: Sermorelin acetate (note moved here). Sermorelin is a 29-amino acid peptide used to treat growth problems caused by growth hormone deficiency (commonly occurring in children). It is the bioactive fragment of human growth hormone releasing factor (GHRH). It is used as a diagnostic reagent. It is a polypeptide and peptide hormone. Sermorelin acetate is an amidated acetate of a synthetic 29-amino acid peptide (GRF 1-29 NH 2 ), corresponding to the N-terminal fragment of naturally occurring human growth hormone releasing hormone (GHRH or GRF), which consists of 44 amino acid residues. It is the bioactive fragment of human growth hormone-releasing factor, composed of GHRH(1-29)-amide. This N-terminal sequence is identical in many mammals, such as humans, pigs, and cattle. It is used to diagnose or treat patients with growth hormone deficiency. See also: Semolorelin (note moved to).
Drug Indications For the treatment of dwarfism, prevention of HIV-induced weight loss Mechanism of Action Semolorelin binds to the growth hormone-releasing hormone receptor, and its ability to stimulate growth hormone secretion is similar to that of natural growth hormone-releasing hormone. Pharmacodynamics Semolorelin is used to treat growth hormone deficiency or growth retardation in children. Glifos increases plasma growth hormone concentration by stimulating the pituitary gland to release growth hormone (GH). Glifos is similar to the full-length natural hormone (44 amino acid residues) in stimulating the secretion of growth hormone in the human body. "Operation Pangoal" is an annual international action week to combat drug crime. In this study, entitled “Operation Resistance,” we asked institutions in European countries to search for counterfeit antibiotics and injectable biopeptides (peptides and proteins) among medicines seized during Operation Pangoal 7 (2014). Belgium, Cyprus, Czech Republic, Denmark, France, Netherlands, Portugal, Sweden, Spain, United Kingdom, Norway, and Switzerland all reported findings. These countries reported seizures of approximately 21,000 doses (e.g., tablets, capsules) of counterfeit antibiotics. The majority of these were commonly used antibiotics without proper authorization. This week, the number of counterfeit injectable biopharmaceuticals reported was extremely small. Counterfeit products reported by laboratories included human growth hormone, sermorepinephrine, melanostatin II, and products without any active ingredients. The average shipment volume appears excessively large and not intended for personal use, suggesting a significant portion of these products are intended for resale. This study outlines the situation of counterfeit antibiotics and biopharmaceuticals entering European countries. It remains unclear how many counterfeit products ultimately reached consumers during Operation Pan-Continental and other weeks. The shipment volumes indicate that the importation of counterfeit antibiotics and biopharmaceuticals is for both personal use and resale. The use of antibiotics of unknown origin can harm health, exacerbate antibiotic resistance, and make it difficult for health authorities to identify sources of infection. Counterfeit biopharmaceuticals also pose health risks because they lack all labeling and may contain unlicensed injectable drugs. Raising awareness among healthcare professionals is crucial, as counterfeit drugs in Europe are not limited to medications for treating erectile dysfunction. [1] |
| Molecular Formula |
C151H250N44O44S
|
|---|---|
| Molecular Weight |
3417.93413305283
|
| Exact Mass |
3355.82
|
| Elemental Analysis |
C, 53.06; H, 7.37; N, 18.03; O, 20.60; S, 0.94
|
| CAS # |
114466-38-5
|
| Related CAS # |
114466-38-5 (acetate); 86168-78-7;
|
| PubChem CID |
16132412
|
| Sequence |
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2.CH3CO2H; L-tyrosyl-L-alanyl-L-alpha-aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-L-asparagyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-glycyl-L-glutaminyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L-alpha-aspartyl-L-isoleucyl-L-methionyl-L-seryl-L-argininamide acetic acid
|
| SequenceShortening |
YADAIFTNSYRKVLGQLSARKLLQDIMSR
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.07
|
| Hydrogen Bond Donor Count |
53
|
| Hydrogen Bond Acceptor Count |
51
|
| Rotatable Bond Count |
118
|
| Heavy Atom Count |
240
|
| Complexity |
7670
|
| Defined Atom Stereocenter Count |
31
|
| SMILES |
S(C)CC[C@@H](C(N[C@H](C(N[C@H](C(N)=O)CCCNC(=N)N)=O)CO)=O)NC([C@H]([C@@H](C)CC)NC([C@H](CC(=O)O)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(=N)N)NC([C@H](C)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CC(C)C)NC([C@H](C(C)C)NC([C@H](CCCCN)NC([C@H](CCCNC(=N)N)NC([C@H](CC1C=CC(=CC=1)O)NC([C@H](CO)NC([C@H](CC(N)=O)NC([C@H]([C@@H](C)O)NC([C@H](CC1C=CC=CC=1)NC([C@H]([C@@H](C)CC)NC([C@H](C)NC([C@H](CC(=O)O)NC([C@H](C)NC([C@H](CC1C=CC(=CC=1)O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.OC(C)=O
|
| InChi Key |
BVLCEKWPOSAKSZ-YQMCHIOTSA-N
|
| InChi Code |
InChI=1S/C149H246N44O42S.C2H4O2/c1-20-77(13)116(191-122(211)81(17)168-132(221)104(66-113(204)205)178-121(210)79(15)167-123(212)88(152)62-84-39-43-86(198)44-40-84)145(234)185-102(63-83-32-23-22-24-33-83)138(227)193-118(82(18)197)146(235)186-103(65-111(155)202)137(226)189-108(71-196)142(231)182-101(64-85-41-45-87(199)46-42-85)136(225)175-93(38-31-56-165-149(161)162)126(215)174-91(35-26-28-53-151)131(220)190-115(76(11)12)143(232)184-97(58-72(3)4)124(213)166-68-112(203)170-94(47-49-109(153)200)128(217)180-100(61-75(9)10)135(224)188-106(69-194)140(229)169-80(16)120(209)172-92(37-30-55-164-148(159)160)125(214)173-90(34-25-27-52-150)127(216)179-99(60-74(7)8)134(223)181-98(59-73(5)6)133(222)176-95(48-50-110(154)201)129(218)183-105(67-114(206)207)139(228)192-117(78(14)21-2)144(233)177-96(51-57-236-19)130(219)187-107(70-195)141(230)171-89(119(156)208)36-29-54-163-147(157)158;1-2(3)4/h22-24,32-33,39-46,72-82,88-108,115-118,194-199H,20-21,25-31,34-38,47-71,150-152H2,1-19H3,(H2,153,200)(H2,154,201)(H2,155,202)(H2,156,208)(H,166,213)(H,167,212)(H,168,221)(H,169,229)(H,170,203)(H,171,230)(H,172,209)(H,173,214)(H,174,215)(H,175,225)(H,176,222)(H,177,233)(H,178,210)(H,179,216)(H,180,217)(H,181,223)(H,182,231)(H,183,218)(H,184,232)(H,185,234)(H,186,235)(H,187,219)(H,188,224)(H,189,226)(H,190,220)(H,191,211)(H,192,228)(H,193,227)(H,204,205)(H,206,207)(H4,157,158,163)(H4,159,160,164)(H4,161,162,165);1H3,(H,3,4)/t77-,78-,79-,80-,81-,82+,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,115-,116-,117-,118-;/m0./s1
|
| Chemical Name |
H-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-NH2
|
| Synonyms |
GHRH (1-29); Sermorelin acetate; trade name: Geref.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.2926 mL | 1.4629 mL | 2.9257 mL | |
| 5 mM | 0.0585 mL | 0.2926 mL | 0.5851 mL | |
| 10 mM | 0.0293 mL | 0.1463 mL | 0.2926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03031535 | Completed | Drug: Intranasal octreotide acetate Drug: Subcutaneous octreotide acetate Diagnostic Test: Growth hormone-releasing hormone Diagnostic Test: Arginine hydrochloride |
Healthy Volunteer Study | Dauntless Pharmaceuticals | 2017-01 | Phase 1 |